Efficacy and Safety of Teicoplanin in CDAD

Summary

Primary Objective: Explore the efficacy of teicoplanin (100-200 mg administered orally twice a day for 7 to 14 days) in patients with Clostridium difficile infection-associated diarrhea and colitis Secondary Objective: Evaluate the safety of teicoplanin in patients with Clostridium difficile infection-associated diarrhea and colitis

Timeline

Start

2020-05-15

Primary completion

2021-01-21

Completion

2021-03-10

Outcome

Outcome not reported

Stopped: “Due to COVID-19 and great challenges during patient enrolment period, current status of this study is far behind the plan. The study cannot be completed according to the plan. Sanofi decides to terminate the study upon comprehensive assessment.”

Drugs

Indications